L15 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:534196 CAPLUS Full-text
DN 141:89125
TI Preparation of oxodiazepanylquinazolinones as modulators of KSP kinesin activity for treatment of proliferative disease.
IN Bergnes, Gustave; Dhanak, Dashyant; Knight, Steven David; Lu, Pu Ping; Morgans, David J., Jr.; Newlander, Kenneth Allen
PA Smithkline Beecham Corporation, USA; Cytokinetics
SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004055008	A1	20040701	WO 2003-US39708	20031212
	W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, EG, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003299612	A1	20040709	AU 2003-299612	20031212
	EP 1581520	A1	20051005	EP 2003-799901	20031212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2006052360	A1	20060309	US 2005-538228	20050608
PRAI	US 2002-433494P	P	20021213		
	US 2002-435001P	P	20021219		
	WO 2003-US39708	W	20031212		

OS MARPAT 141:89125
GI



I

AB Title compds. [I; R1-R4 = H, halo, OH, NO2, cyano, (substituted) alkyl, alkoxy, aryl, heteroaryl, etc.; R5, R51 = H, (substituted) alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl; R5R51C = 3-7 membered carbocyclyl; R6 = H, (substituted) alkyl, aryl, aralkylo, heteroaryl, heteroaralkyl; R7, R71, R8, R81, R9, R91 = H, (substituted) alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl; X, Y = CR10R11, NR12, O, S; R10, R11 = H, (substituted) alkyl, aryl, heteroaryl; R12 = H, (substituted) alkyl, aralkyl, heteroaralkyl, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, aralkylcarbonyl, heteroaralkylcarbonyl, alkoxycarbonyl, etc.], were prepared Thus, N-(2-aminoethyl)-N-[1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin- 2-yl)-2-methylpropyl]acrylamide (preparation given) was refluxed overnight in MeOH to give 3-benzyl-7-chloro-2-[2-methyl-1-(7-oxo-1,4-diazepan-1- yl)propyl]-3H-quinazolin-4-one. Some I inhibited cell proliferation with GI50 <10 nM.

IT **713526-19-3P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)
(claimed compound; preparation of oxodiazepanylquinazolinones as modulators of KSP kinesin activity)

RN 713526-19-3 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-2-[1-(hexahydro-7-oxo-1H-1,4-diazepin-1-yl)-2-methylpropyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **713526-20-6P 713526-21-7P 713526-22-8P**
713526-23-9P 713526-24-0P 713526-25-1P
713526-26-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)(claimed compound; preparation of oxodiazepanylquinazolinones as modulators of KSP kinesin activity)

RN 713526-20-6 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-2-[1-(hexahydro-4-methyl-7-oxo-1H-1,4-diazepin-1-yl)-2-methylpropyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 713526-21-7 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-2-[(1R)-1-(hexahydro-7-oxo-1H-1,4-diazepin-1-yl)-2-methylpropyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 713526-22-8 CAPLUS

CN 5H-1,4-Diazepin-5-one, 1-acetyl-4-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]hexahydro- (9CI) (CA INDEX NAME)



RN 713526-23-9 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-2-[1-(hexahydro-3,3-dimethyl-7-oxo-1H-1,4-diazepin-1-yl)-2-methylpropyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 713526-24-0 CAPLUS
CN 4(3H)-Quinazolinone, 7-chloro-2-[1-[hexahydro-7-oxo-4-(phenylmethyl)-1H-1,4-diazepin-1-yl]-2-methylpropyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 713526-25-1 CAPLUS
CN 4(3H)-Quinazolinone, 7-chloro-2-[1-(hexahydro-7-oxo-1H-1,4-diazepin-1-yl)propyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 713526-26-2 CAPLUS
CN 4(3H)-Quinazolinone, 7-chloro-2-[1-(hexahydro-6,6-dimethyl-7-oxo-1H-1,4-diazepin-1-yl)-2-methylpropyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:573666 CAPLUS Full-text
DN 133:164010
TI Preparation of caprolactams, piperidinones, and pyrrolidinones as Factor Xa inhibitors in prevention or treatment of thromboses, coronary artery disease, or cerebrovascular disease in mammals
IN Stein, Philip D.; Bisacchi, Gregory S.; Shi, Yan; O'Connor, Stephen P.; Li, Chi
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 284 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000047207	A1	20000817	WO 2000-US2883	20000202
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2360305	AA	20000817	CA 2000-2360305	20000202
	US 6297233	B1	20011002	US 2000-496571	20000202
	EP 1156803	A1	20011128	EP 2000-914505	20000202
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	AU 760174	B2	20030508	AU 2000-35887	20000202
PRAI	US 1999-119372P	P	19990209		
	US 1999-167428P	P	19991124		
	WO 2000-US2883	W	20000202		

OS MARPAT 133:164010
GI



I



II

AB Title chiral compds. [I; R = CN, CONH2, COOCH2CH3, COC6H5, SO2NH2, OCH3, SO2N(CH3)2, SO2CH3, arylsulfonyl, heterocyclosulfonyl, (un)substituted Ph, heterocyclyl, heterocycleocarbonyl, alkoxylcarbonyl, arylaminocarbonyl; R1 = H, arylalkyl; R2 = alkyl, (un)substituted Ph, benzoheterocyclyl, cyclopentyl; R3 = heterocyclylamino, heterocyclyl, alkoxy, cycloalkylamino, OH; n = 0, 1, 2] , pharmaceutically acceptable salts, and stereoisomers are pred. as Factor

Xa inhibitors and are useful as anticoagulants (no data). A method for treating cardiovascular diseases associated with thromboses is also provided. Thus, the title compound II was prepared

IT **288075-92-3P 288079-50-5P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of caprolactams as Factor Xa inhibitors in prevention or treatment of thromboses, coronary artery disease, or cerebrovascular disease in mammals)

RN 288075-92-3 CAPLUS

CN Pyrrolidine, 1-[[(3S)-3-[[(cyanoamino)[(1,4-dihydro-4-oxo-6-quinazolinyl)amino]methylene]amino]hexahydro-2-oxo-1H-azepin-1-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288079-50-5 CAPLUS

CN Benzamide, N-[[(1,4-dihydro-4-oxo-6-quinazolinyl)amino][[(3S)-hexahydro-2-oxo-1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1H-azepin-3-yl]amino]methylene]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:661888 CAPLUS Full-text
DN 132:60611
TI The reactivity of the 2-deoxyribonolactone lesion in single-stranded DNA and its implication in reaction mechanisms of DNA damage and repair
AU Hwang, Jae-Taeg; Tallman, Keri A.; Greenberg, Marc M.
CS Department of Chemistry, Colorado State University, Fort Collins, CO, 80523, USA
SO Nucleic Acids Research (1999), 27(19), 3805-3810
CODEN: NARHAD; ISSN: 0305-1048
PB Oxford University Press
DT Journal
LA English
AB The formal C1'-oxidation product, 2-deoxyribonolactone, is formed as a result of DNA damage induced via a variety of agents, including γ-radiolysis and the enediyne antitumor antibiotics. This alkaline labile lesion may also be an intermediate during DNA damage induced by copper-phenanthroline. Oligonucleotides containing this lesion at a defined site were formed via aerobic photolysis of oligonucleotides containing a photolabile ketone, and were characterized by gel electrophoresis and electrospray mass spectrometry (ESI-MS). Treatment of oligonucleotides containing the lesion with secondary amines produces strand breaks consisting of 3'-phosphate termini, and products which migrate more slowly in polyacrylamide gels. MALDI-TOF mass spectrometry anal. indicates that the slower moving products are formal adducts of the β-elimination product resulting from 2-deoxyribonolactone and one mol. of amine. The addition of β-mercapto-ethanol to the reaction mixture produces thiol adducts as well. The stability of these adducts suggests that they cannot be the labile species characterized by gel electrophoresis in copper-phenanthroline-mediated strand scission. The characterization of these adducts by mass spectrometry also provides, by analogy, affirmation of proposals regarding the reactivity of nucleophiles with the β-elimination product of abasic sites. Finally, the effects of this lesion and the various adducts on DNA repair enzymes are unknown, but their facile generation from oligonucleotides containing a photolabile ketone suggests that such issues could be addressed.
IT **252667-51-9P**
RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(reactivity of 2-deoxyribonolactone lesion in single-stranded DNA and its implication in reaction mechanisms of DNA damage and repair)
RN 252667-51-9 CAPLUS
CN 3'-Adenylic acid, 2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy-, 3'-[2-(hexahydro-1,4-dimethyl-7-oxo-1H-1,4-diazepin-5-yl)-2-hydroxyethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 2-A







RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:665082 CAPLUS Full-text
DN 127:293592
TI Efficient Syntheses of Pyrofolic Acid and Pteroyl Azide, Reagents for the Production of Carboxyl-Differentiated Derivatives of Folic Acid
AU Luo, Jin; Smith, Michael D.; Lantrip, Douglas A.; Wang, Susan; Fuchs, P. L.
CS Department of Chemistry, Purdue University, West Lafayette, IN, 47907, USA
SO Journal of the American Chemical Society (1997), 119(42), 10004-10013
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
OS CASREACT 127:293592
GI



I



II

AB Reaction of fôlic acid (I; R = L-Glu-OH) with excess trifluoroacetic anhydride provides access to both the previously unknown N10-(trifluoroacetyl)pyrofolic acid (II; R1 = COCF3) and pyrofolic acid (II; R1 = H). Reaction of either of these materials with hydrazine selectively affords pteroyl hydrazide (I; R = NHNH2), which may be oxidized to pteroyl azide (I; R = N3) on a large scale (62% overall from folic acid without the need for chromatog.). Treatment of I (R = N3) with differentially protected glutamates provides a convenient and high-yielding synthesis of differentially protected, optically pure folates.

IT **197151-84-1P**
RL: BYP (Byproduct); PREP (Preparation)
(efficient syntheses of pyrofolic acid and pteroyl azide as reagents for the production of carboxyl-differentiated folic acid derivs.)

RN 197151-84-1 CAPLUS
CN Benzamide, 4-[[(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]- (9CI) (CA INDEX NAME)



RE.CNT 82 THERE ARE 82 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1994:435622 CAPLUS Full-text
DN 121:35622
TI Angiotensin II receptor antagonist 2,3,6-substituted quinazolinones
IN Albright, Jay D.
PA American Cyanamid Co., USA
SO U.S., 33 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5288720	A	19940222	US 1993-52940	19930423
PRAI US 1993-52940		19930423		

OS MARPAT 121:35622
GI



I

AB The title compds. [I; R6 = (un)substituted heterocyclylalkyl; X = (un)branched C3-5 alkyl], useful for the treatment of hypertension and congestive heart failure, are prepared Thus, I (R6 = Q, X = Bu), was prepared and demonstrated beef adrenal gland-derived angiotensin II receptor binding (IC50) of 13.0 X 10-8 M.

IT **155399-94-3P 155399-95-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as angiotensin II receptor antagonist)

RN 155399-94-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-butyl-6-[1-(hexahydro-1-methyl-2-oxo-1H-azepin-3-yl)-1-hydroxyethyl]-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 155399-95-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-butyl-6-[1-(hexahydro-1-methyl-2-oxo-1H-azepin-3-yl)-1-hydroxyethyl]-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L15 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:571368 CAPLUS Full-text
DN 117:171368
TI Synthesis of 5-fluoro-2-methyl-3-(2-trifluoromethyl-1,3,4-thiadiazol-5-yl)-4(3H)-quinazolinone and related compounds with potential antiviral and anticancer activity
AU Parkanyi, Cyril; Yuan, Hui Liang; Stroemberg, Bo H. E.; Evenzahav, Ariella
CS Dep. Chem., Florida Atlantic Univ., Boca Raton, FL, 33431-0991, USA
SO Journal of Heterocyclic Chemistry (1992), 29(4), 749-53
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
OS CASREACT 117:171368
GI



I



II



III



IV

AB The synthesis of ten new substituted 1,3,4-thiadiazolyl-4(3H)- quinazolinones I (X1 = X2 = H, Br, X3 = F, Cl, X4 = CF3, CMe3, Et, cyclopropyl) and II is reported. Compds. I (where X1 = X2 = H, X3 = F) were prepared by condensation of 5-fluoro-2-methyl-3,1-benzoxazin-4-one (3) and 5-substituted 2-amino-1,3,4-thiadiazoles. Compound II was obtained by condensation of 3 with DL-α-amino-ε-caprolactam (12). Compound I (X1 = Br, X2 = X3 =H, X4 = CMe3) was synthesized by condensation of 6-bromo-2-methyl-3,1-benzoxazin-4-one (16) and 2-amino-5-t-butyl-1,3,4- thiadiazole (5). Compds. I (X1 = X2 = Br, X3 = Cl) were obtained by condensation of 5-chloro-6,8-dibromo-2-methyl-3,1-benzoxazin-4-one (19) and 5-substituted 2-amino-1,3,4-thiadiazoles, resp. The substituted 3,1-benzoxazine-4-ones, e.g., III, 16, and 19 were obtained in good yield by refluxing the appropriate anthranilic acid, e.g., IV, with acetic anhydride.
IT **143769-23-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 143769-23-7 CAPLUS
CN 4(3H)-Quinazolinone, 5-fluoro-3-(hexahydro-2-oxo-1H-azepin-3-yl)-2-methyl- (9CI) (CA INDEX NAME)



L15 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1991:23978 CAPLUS Full-text
DN 114:23978
TI Preparation of quinazolinone derivatives as anti-tumor agents
IN Hughes, Leslie Richard; Oldfield, John; Pegg, Stephen John; Barker, Andrew John; Marsham, Peter Robert
PA Imperial Chemical Industries PLC, UK; National Research Development Corp.
SO Eur. Pat. Appl., 65 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 373891	A2	19900620	EP 1989-312986	19891212
	EP 373891	A3	19901205		
	EP 373891	B1	19941102		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	NO 8904692	A	19900618	NO 1989-4692	19891124
	AU 8945883	A1	19900621	AU 1989-45883	19891204
	ZA 8909481	A	19900829	ZA 1989-9481	19891212
	ES 2063830	T3	19950116	ES 1989-312986	19891212
	GB 2227016	A1	19900718	GB 1989-28146	19891213
	GB 2227016	B2	19920715		
	CA 2005476	AA	19900615	CA 1989-2005476	19891214
	US 5089499	A	19920218	US 1989-450670	19891214
	DK 8906366	A	19900616	DK 1989-6366	19891215
	JP 02218668	A2	19900831	JP 1989-324135	19891215
	US 5252573	A	19931012	US 1991-793183	19911118
	US 5395838	A	19950307	US 1993-91828	19930713
PRAI	GB 1988-29296	A	19881215		
	US 1989-450670	A3	19891214		
	US 1991-793183	A3	19911118		

OS MARPAT 114:23978
GI



I

AB Title compds. I (R4 = H, H2N, C1-6 alkyl, C1-6 alkoxy, substituted C1-3 alkyl, C1-3 hydroxyalkoxy, C1-6 alkoxyalkoxy; R2 = H, C1-6 alkyl, -alkenyl, -alkynyl, -hydroxyalkyl, -haloalkyl, -cyanoalkyl; Ar = (substituted) phenylene, -heterocyclene; L = CONH, NHCO, CH:CH, etc.; Y = C1-10 aryl, -hydrogenated aryl, -heteroaryl, etc.) or a pharmaceutically-acceptable salt thereof, are prepared (PhO)2PON3 and Et3N were added successively to a mixture of p-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-methyl)-N-prop-2-ynylamino]benzoic acid-trifluoroacetic acid salt and DMSO. The mixture was stirred for 5 h followed by 3-(aminomethyl)pyridine to give I (R1 = H; R2 = HC.tplbond.CCH2; ArL = C6H4CO; Y = 3-pyridylmethyl). Similarly prepared was I (R1 = Me; R2 = HC.tplbond.CCH2, L = NHCO; Y = 2-pyridylmethyl) (II). II showed an IC50 of 3.9 μM against L1210 cell line. Pharmaceutical formulations comprising I are given.

IT **131052-26-1P 131052-27-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antitumor agent)

RN 131052-26-1 CAPLUS
CN Benzamide, 4-[[(1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]-2-propynylamino]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 131052-27-2 CAPLUS
CN Benzamide, 4-[[(1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]- (9CI) (CA INDEX NAME)



```
=> d l2; d l11; d his; log y
L2 HAS NO ANSWERS
L1                STR
```






```
 G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.
L2                QUE  ABB=ON   PLU=ON   L1

L11 HAS NO ANSWERS
L10               STR
```






```
 G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.
L11               QUE  ABB=ON   PLU=ON   L10

     (FILE 'REGISTRY' ENTERED AT 16:24:46 ON 24 MAR 2006)
                  DEL HIS Y
L1                STRUCTURE UPLOADED
L2                QUE L1
L3              1 S L2
L4             39 S L2 FUL
L5                STRUCTURE UPLOADED
L6                QUE L5
L7              1 S L6 SAM SUB=L4
L8             39 S L6 FUL SUB=L4
```

```
     FILE 'CAPLUS' ENTERED AT 16:27:33 ON 24 MAR 2006
L9           12 S L8

     FILE 'REGISTRY' ENTERED AT 16:29:12 ON 24 MAR 2006
L10             STRUCTURE UPLOADED
L11             QUE L10
L12           0 S L11 SAM SUB=L4
L13          18 S L11 FUL SUB=L4
L14          21 S L4 NOT L13

     FILE 'CAPLUS' ENTERED AT 16:30:00 ON 24 MAR 2006
L15           7 S L14


COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      36.69     514.04

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -5.25     -14.25

STN INTERNATIONAL LOGOFF AT 16:30:55 ON 24 MAR 2006
```